Skip to main content

Table 1 Relevant Clinico-pathological features of the assessed ER + Breast cancer patients (n = 97)

From: Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer

Characteristic

Value

Age at breast cancer diagnosis (y), median (range)

44.65 ± 6.38

Age at menarche

12.80 ± 1.82

Family status

Single

17 (17.5%)

Married

80 (82.5%)

Surgery

Breast conserving, n (%)

87 (89.7%)

Mastectomy, n (%)

10 (10.3%)

Chemotherapy, n (%)

Adjuvant

77 (79.3%)

Neo adjuvant

20 (20.7%)

Tumor size

 ≤ 2 cm

29 (29.9%)

2 < size ≤ 5 cm

58 (59.8%)

 > 5 cm

10 (10.3%)

Grade

I

8 (8.3%)

II

62 (63.9%)

III

27 (27.8%)

Node status

pN + , n (%)

90 (92.78%)

pN0, n (%)

7 (7.22%)

HER2 status

HER2 + , n (%)

31 (32%)

HER2 − , n (%)

66 (68%)

Histologic type of tumor

Ductal

2.8%

Lobular

6.9%

Other types

90.3%

Distant metastatic site

No recurrence

80 (82.5%)

Locally

11 (11.3%)

Metastatic

6 (6.2%)

  1. Tumor size extracted from pathological report, or for neoadjuvant treated patients, the largest size recorded including clinical measurement. Tumors considered ER+ if ≥ 10% of the cells stained positive for the receptor by immunohistochemistry, Grade classified according to the Nottingham histologic grade N+ = regional lymph node metastasis; N0 = no regional lymph node metastasis. RLR relapse loco-region